In Vitro Studies of the Activity of Dithiocarbamate Organoruthenium Complexes against Clinically Relevant Fungal Pathogens

Claudio L. Donnici 1*, Luciano J. Nogueira 1, Maria Helena Araujo 1, Sheila Rodrigues Oliveira 1, Thais F. F. Magalhães 2, Miriam T. P. Lopes 3, Ana Cândida Araújo e Silva 3, Ana Maria da Costa Ferreira 4, Cleide V. B. Martins 2,5 and Maria A. de Resende Stoianoff 2

1 Departamento de Química, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, CEP 31270-901, Belo Horizonte, MG, Brazil
2 Departamento de Microbiologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, CEP 31270-901, Belo Horizonte, MG, Brazil
3 Departamento de Farmacologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antonio Carlos, 6627, CEP 31270-901, Belo Horizonte, MG, Brazil
4 Instituto de Química da Universidade de São Paulo, Av. Lineu Prestes, 748, CEP 05508-900, São Paulo, SP, Brazil
5 Gemaq–UNIOESTE, Rua da Faculdade, CEP, 85903-000, Toledo, PR, Brazil

* Author to whom correspondence should be addressed; E-Mail: cdonnici@ufmg.br; Tel.: +55-31-3409-5745; Fax: +55-31-3409-5700.

Received: 26 February 2014; in revised form: 17 April 2014 / Accepted: 22 April 2014 / Published: 24 April 2014

Abstract: The in vitro antifungal activity of nine dirutheniumpentadithiocarbamate complexes C1–C9 was investigated and assessed for its activity against four different fungal species with clinical interest and related to invasive fungal infections (IFIs), such as Candida spp. [C. albicans (two clinical isolates), C. glabrata, C. krusei, C. parapsolisis, C. tropicalis, C. dubliniensis (six clinical isolates)], Paracoccidioides brasiliensis (seven clinical isolates), Cryptococcus neoformans and Sporothrix schenckii. All synthesized complexes C1–C9 and also the free ligands L1–L9 were submitted to in vitro tests against those fungi and the results are very promising, since some of the obtained MIC (minimal inhibitory concentration) values were very low (from $10^{-6}$ mol mL$^{-1}$ to $10^{-8}$ mol mL$^{-1}$) against all investigated clinically relevant fungal pathogens, except for C. glabrata, that the MIC values are close to the ones obtained for fluconazole, the standard antifungal agent tested. Preliminary structure-activity relations (SAR) might be suggested and a strong
influence from steric and lipophilic parameters in the antifungal activity can be noticed. Cytotoxicity assays (IC\textsubscript{50}) showed that the complexes are not as toxic (IC\textsubscript{50} values are much higher—30 to 200 fold—than MIC values). These ruthenium complexes are very promising lead compounds for novel antifungal drug development, especially in IFIs, one of most harmful emerging infection diseases (EIDs).

Keywords: emerging infectious diseases; invasive fungal infections; dinuclear pentakis-dithiocarbamateruthenium complexes; antifungal susceptibility; cytotoxicity testing; Candida spp; Paracoccidioides brasiliensis; Cryptococcus neoformans; Sporothrix schenckii

1. Introduction

Emerging infectious diseases (EIDs) are a significant burden on global economies and public health [1]. It is noteworthy that fungi infect billions of people every year, yet their contribution to the global burden of disease is largely unrecognized; in fact, opportunistic invasive fungal infections (IFIs) are a major cause of morbidity and mortality in immunocompromised patients [2,3]. In addition, these severe well-known emerging diseases are difficult to diagnose and subsequent usage of appropriate antifungal therapy is difficult [4]. Besides, this worldwide public health situation has also become alarming [2,3] because of the increase in the frequency of isolation of resistant fungi species even in Brazil [5]. A majority of mycoses-related deaths are associated with Candida, Aspergillus and Cryptococcus spp. infections [6,7]. Among the cited fungi paracoccidioidomycosis (PCM), caused by Paracoccidioides brasiliensis is the predominant systemic mycosis in Latin America, causing half of the total deaths from fungal infectious diseases in Brazil. Between 1996 and 2006, most fatal cases occurred among adults between the ages of 30 and 59 years, with approximately 87% of fatalities in men [8]. P. brasiliensis is another severe IFI cause, it is sensitive to multiple chemotherapeutic drugs, but very long periods of treatment are expected in these cases, which are monitored by clinical, radiological, and serological follow-up; besides, various interactions of chemotherapeutics against PCM and other drugs are listed in the 2006 PCM guidelines and in several cases the azolic drugs cannot be used [8].

For many years, despite its high toxicity, amphotericin B (AMB) has been the bedrock of systemic antifungal therapy, however fungal resistance has been observed specially in candidiasis cases [9–11]. Imidazoles and triazoles (“azoles”) are the largest class of antifungal agents in clinical use [12]. Fluconazole (FLU), the first of them to be used (since 1990), was considered during the 90s “the gold standard” [11–13] for the treatment of fungal infections, although due to their indiscriminate use cases of resistance to this drug have been observed [14]. Itraconazole is also very used, especially in the treatment of fungal infections caused by Aspergillus and Sporotrix that usually are non-susceptible to fluconazole [15], but itraconazole is very hydrophobic, very toxic and drug resistance cases have also been observed to this azole since 1997 [16]. The novel generation of triazoles [17]—voriconazole and posaconazole—approved by FDA in 2002 and 2006, respectively, present a broad action-spectrum against fungal species as Candida, Aspergillus, Fusarium, Penicillium, Scedosporium, Acremonium and Trichosporon and it is also active against dermatophytes and dimorphic fungi and Cryptococcus.
Although interactions with other drugs are similar to those ones presented by fluconazole and itraconazole, there are ever fungi resistant to these drugs and also cross-resistance to new generation triazoles [12,14]. Ravuconazole [20] is another of the most successful antifungal class in the clinic and stands out for its unusually long plasma half-life in humans [12], besides it is clearly an “extended-spectrum” triazole with potent in vitro activity against these rare and potentially “emerging” opportunistic pathogens [21]. However, it has already been related variable cross-resistance to posaconazole, voriconazole, and even ravuconazole. Cross-resistance between fluconazole and ravuconazole applies most directly to fluconazole-resistant C. glabrata and is variable among other species of Candida [22]. It is also noteworthy to mention the triazole-resistant fungi description with itraconazole, posaconazole, voriconazole, isavuconazole, or ravuconazole [23]. The last and the newest class of antifungal agents are echinocandins (caspofungin, micafungin and anidulafungin, respectively since 2001, 2005 and 2006) [24,25], that are successors of cilofungin, which was abandoned in the 1980s. In fact, the echinocandins represent the first novel target in 20 years of antifungal drug discovery in terms of clinically useful drugs. The fungal resistance to echinocandins is rare, but the mutation in the target (FKS1) is a common mechanism of the resistance to these drugs [10,26]. This mutation minimizes the drug impact in the fungus cell wall and this has been demonstrated for C. albicans, C. glabrata, C. krusei, C. tropicalis and C. dubliniensis generating a cross-resistance to all class of echinocandins [27]. The resistance of C. glabrata to echinocandins has been associated to FKS2 gene mutation [27] while the resistance to Cryptococcus neoformans is related to the different polysaccharide composition of the cell wall in this species [14]. As with all antimicrobial agents, the spectra of emergence of resistance is a real one, and appropriate vigilance in the arms race between fungi and humans means that new targets and new inhibitors will continue to be required for effective antifungal therapy in the future [11,27].

Antifungal agents have also been used in agriculture, among them, the dithiocarbamates are remarkable as worldwide agricultural fungicides, since 1934, when thiram (bis(dimethylthiocarbamoyl)disulfide) was introduced as a seed treatment [28–32]. For this purpose, since 1950s dithiocarbamate complexes mainly with ethylenebisdithiocarbamate (EBDC) as ligand and zinc and manganese as metal center (known as zireb or ziram, and maneb or mancozeb, respectively) have been broadly used [33]. Other dithiocarbamate complexes with different metallic centers and antifungal activity have been investigated [34–40], but the application of dithiocarbamate compounds against human mycoses is relatively rare [38,40]. There is a remarkable study about the antifungal activity of dithiocarbamateorganotin (IV) compounds [41,42] and, besides, there are some studies involving ruthenium coordination compounds activities against filamentous fungi [43–49]; some of them are related to Ru(II) [36,43,47,49] and others to Ru(III) oxidation states [45,48]. Nevertheless, the first work that describes the investigation of dithiocarbamate ruthenium (III) complexes as antifungal agent [50] has been developed by our own research group, and in this work the susceptibility of seven different species of Aspergillus (A. clavatus, A. flavus, A. fumigatus (ATCC 16913 and CI, clinical isolated), A. niger, A. nomius, A. tamarii and A. terreus) was tested with promising results considering that Aspergillus spp. has also became a recognized pathogen related to IFIs [51,52]. It is remarkable that in some cases [43,50] the ruthenium complexes showed higher activity than the corresponding free ligands. In fact, the study of metal-based drugs represent a therapeutic alternative for novel drug discovery [53,54] and in this way ruthenium complexes provide a rich platform and suitable building
blocks for the design of novel bioactive compounds, once the biological activity of the organic ligand is known, due to the specific properties inherent of the transition metal center [55,56]. It is noteworthy that the investigation of novel ruthenium dithiocarbamate complexes as novel and promising drugs is more common for anticancer chemotherapy [55–58] and also in this area it can be observed that dithiocarbamate chelation with ruthenium can enhance the activity [57]. In the present work, nine ruthenium dithiocarbamate compounds (Figure 1, C1–C9), and their corresponding free ligands, with potential antifungal activity were tested and compared with AMB and fluconazole (FLC) against four different fungal species with clinical interest and related to emerging infectious diseases (EIDs) and invasive fungal infections (IFIs), such as Candida spp. (C. albicans, two clinical isolates), C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis (six clinical isolates), Paracoccidioides brasiliensis (seven clinical isolates), Cryptococcus neoformans and Sporothrix schenckii.

**Figure 1.** General structure of the studied diruthenium pentakis-dithiocarbamate complexes (C1–C9).

\[ \text{C1} - R_1 = R_2 = \text{CH}_3 \]
\[ \text{C2} - R_1 = R_2 = \text{CH}_2\text{CH}_3 \]
\[ \text{C3} - R_1 = (\text{CH}_3)_3 R_2 = \text{H} \]
\[ \text{C4} - R_1 = \text{CH}(\text{CH}_3)_2 R_2 = \text{H} \]
\[ \text{C5} - R_1 = R_2 = \text{CH}(\text{CH}_3)_2 \]
\[ \text{C6} - R_1 = R_2 = (-\text{CH}_2)_4 \]
\[ \text{C7} - R_1 = R_2 = (-\text{CH}_2)_5 \]
\[ \text{C8} - R_1 = R_2 = (-\text{CH}_2)_2\text{O}(\text{CH}_2)_2^- \]
\[ \text{C9} - R_1 = R_2 = -\text{CH}_2\text{C}_6\text{H}_5 \]

2. Results and Discussion

2.1. Chemistry

All dithiocarbamate ligands L1–L9 were synthesized in good yields (63%–93%) as described elsewhere [42,50] through the usual procedure starting from the corresponding substituted amines and carbon disulfide (CS₂); all ligands were obtained as pure products and have been well-characterized by the usual techniques (IR, ESI-MS, $^1$H and $^{13}$C-NMR spectra and elemental analysis). The coordination reaction between ruthenium (III) trichloride and the nine recently prepared dithiocarbamate ligands (L1–L9) (1:3 mol/mol, in ethanol) afforded nine pentakis(dithiocarbamate)diruthenium complexes C1–C9 (C1: N,N-dimethyl-; C2: N,N-diethyl-; C3: N-mono-tert-butyl-; C4: N-mono-(iso-propyl)-; C5: N-di-(iso-propyl)-; C6: N-pirrolidinyl-; C7: N-piperidinyl-; C8: N-morpholinyl- and C9: N,N-dibenzyl-dithiocarbamates) in 65%–79% yield. The complete chemical characterization was made by several physicochemical techniques (measurement of magnetic susceptibility ($\mu_{\text{eff}}$), electron paramagnetic resonance (EPR) spectra, conductivity, cyclic voltammetry) and spectrometric methods (IR, ESI-MS, $^1$H and $^{13}$C-NMR spectra) [50,59–62]. All compounds were obtained in high purity level (TLC, HPLC and ESI(+)-MS) and the analysis of the results obtained by ESI-(+)–MS spectrometry suggested the general formula of [Ru₂(Ln)₅] for all diruthenium pentadithiocarbamate complexes. In fact, the ESI-MS (positive and negative modes) indicated that the compounds are dinuclear neutral species, besides no chloride as counteranion was detected. If the chloride would be present, we should have seen an expected characteristic peak for chloride ($^{37}$Cl/$^{35}$Cl with a 1:3 ratio). The multiple
fragmentation pattern observed in the ESI-MS spectra corroborates the obtaining of unsymmetrical dinuclear ruthenium complexes in which the dithiocarbamate moiety plays function as bridging ligand, since the presence of fragments that only can be formed through non-equivalent types of ruthenium-sulfur bonds is noticed, and if the compounds would be symmetrical (as in a mononuclear ruthenium complex or in a kind of oligomeric derivative) the fragmentation pattern would be much less complicated; this discussion will be reported further. There is a recent study [63] about the UV-MALDI mass spectrometry investigation of well-known dithiocarbamate complexes (zinc, iron and manganese derivatives) that corroborates our structural proposal, since in this case symmetrical species (monomeric, dimeric, or tetrameric) were obtained and the corresponding mass spectra are not as complicated, as expected, compared to those in this present study. In addition, the analysis of magnetic susceptibility of the studied compounds showed values consistent with the proposed Ru(II)/Ru(III) system.

The proposal of a dinuclear Ru-Ru system is also corroborated by the infrared bands of $\nu$(Ru-Ru) $\approx$ 205 cm$^{-1}$) and $\nu$(S-Ru-S) $\approx$ 280 cm$^{-1}$). The former band associated with $\nu$(Ru-Ru) should be IR-inactive due to the expected high symmetry of the system, nevertheless the observation of this band as cited elsewhere [60] may indicate a distorted octahedral geometry around the diruthenium center. The electrochemical investigation by cyclic voltammetry also indicates that the complexes contain a neutral Ru(II)/Ru(III) system. Analysing the EPR results (Figure 2) for the prepared dithiocarbamate complexes, typical EPR signal of ruthenium(III) ions in the low spin 4d$^3$ configuration can be seen, as shown in Figure 2 (for complexes C2 (Figure 2a) and C4 (Figure 2b)); the spike at 3,400 G ($g \approx$ 2.00) in Figure 2b is probably due to an organic decomposition product. It can be suggested that the obtained ruthenium compounds correspond to Ru(II)/Ru(III) mixed-valent states complexes, similar to a species already described in the literature, $[\text{Ru}_2(\text{acac})_4(\mu-Q)]^+$, where acac = 2,4-pentanedionate, and Q is a quinonoid group, with two equivalent $\pi$-conjugated $\alpha$-diimine chelate sites, and one $p$-quinone function [64]. Those species can have different oxidation states accessible due to an intramolecular electron transfer, forming $[\text{Ru}^{III}(\mu-Q^2)\text{Ru}^{II}]$ or $[\text{Ru}^{II}(\mu-Q^-)\text{Ru}^{II}]$. In the case of the dithiocarbamate ligands studied, formation of a radical species is also possible, giving rise to $[\text{Ru}^{II}L_2(\mu-L)\text{Ru}^{III}L_2]$ or $[\text{Ru}^{II}L_2(\mu-L')\text{Ru}^{II}L_2]$ complexes.

Figure 2. EPR spectra registered in solid state, at 77K, for complexes (a) C2 (α-pentakis(N,N-dietyldithiocarbamate)diruthenium $[\text{Ru}_2(\text{S}_2\text{CN(\text{CH}_2\text{CH}_3)}_2)\text{S}]$) (b) C4 (α-pentakis(N-isopropylidithiocarbamate)diruthenium), $[\text{Ru}_2(\text{S}_2\text{CN(\text{CH}(\text{CH}_3)}_2)\text{S}]$. 

![EPR spectra registered in solid state, at 77K, for complexes (a) C2 (α-pentakis(N,N-dietyldithiocarbamate)diruthenium $[\text{Ru}_2(\text{S}_2\text{CN(\text{CH}_2\text{CH}_3)}_2)\text{S}]$) (b) C4 (α-pentakis(N-isopropylidithiocarbamate)diruthenium), $[\text{Ru}_2(\text{S}_2\text{CN(\text{CH}(\text{CH}_3)}_2)\text{S}]$.]
2.2. Antifungal Assays

This study is one of the first approaches to the investigation of the potential usefulness of organoruthenium complexes as antifungal agents that could be used in IFIs. Activities have been determined against a limited number of isolates fungi, but they are representative of important filamentous fungal pathogens in humans.

The antifungal tests were carried out for all ruthenium complexes C1–C9 and the corresponding free dithiocarbamate ligands L1–L9, against six species (a total of thirteen different strains) of *Candida* spp. (Table 1), the most common fungal pathogen in IFIs [6,7]. In 96% of the cases the ruthenium complexes were more active than the corresponding free ligands (by 3-45 fold). It is important to notice that ruthenium trichloride (control test) did not show any significant antifungal activity for any of the studied microorganisms (>512 µg mL⁻¹/196 × 10⁻⁵ mol L⁻¹). The most susceptible species were *C. albicans* ATCC (Table 1) and the clinical isolates 119CL and 01CL. Considering these three species the MIC decreasing activity order is: C7 > C6 > C2 > C1 > C5 > C9 > C8 > C3 > C4. The most potent complexes C7 and C6 showed very low MIC values (0.40 and 0.43 × 10⁻⁵ mol L⁻¹, respectively) that are comparable to the FLU result (0.33 × 10⁻⁵ mol L⁻¹). Then, in a decreasing bioactivity order the complexes: C2 > C1 > C5 > C9 and C8 are the most active ones (0.85, 1.0, 2.9, 4.1 and 6.3 × 10⁻⁵ mol L⁻¹, respectively) and even the last and less potent complexes—C3 and C4—are still quite active (6.8 and 7.33 × 10⁻⁵ mol L⁻¹, respectively). The clinical isolate C. *albicans* 01CL was also very susceptible to the complexes in a similar decreasing (C7 > C2 ≥ C6 > C1 > C9 > C5 > C4 > C8 > C3) and with close MIC values, although a little higher (1.6–13.6 × 10⁻⁵ mol L⁻¹) when compared to *Candida* ATCC. These data reveal a significant relevancy of these ruthenium complexes as possible novel antifungal agent against IFIs, commonly related to candidiasis, and although AMB could be used, this drug is highly toxic, with low stability and fungal resistance to it has been observed [9–11]. It can be noticed that the similar alkyl chain substituted pyrrolidinyl, ethyl, piperidinyl and the methyl derivatives C7, C2, C6 and C1 show the higher activity, while the mono-N-alkyl analogues, C4 (mono-N-isopropyl) and C3 (mono-N-isopropyl), and the morpholine derivative (C8) are the less active ones.

Among the others studied *Candida* spp. (C. *krusei*, C. *parapsilosis*, C. *tropicalis* and C. *glabrata*) (Table 1), all studied complexes showed also good MIC results: 1.70–7.3, 0.8–4.1, 0.8–7.3 and 4.0–29.3 × 10⁻⁵ mol L⁻¹, respectively and once more the ruthenium complexes were always more active than the corresponding free ligands (by 2–45 fold). Besides, C. *krusei* and C. *parapsilosis* are the most susceptible species and C. *glabrata* is the less susceptible one (Table 1). The most potent complexes against C. *parapsilosis* are C7, C2 and C6 (MIC: 0.80, 0.85 and 0.86 × 10⁻⁵ mol L⁻¹) and it is observed that these three complexes are almost as potent as FLU (0.33 × 10⁻⁵ mol L⁻¹), generally the first drug option for drug-resistant fungal disease. Again, similar decreasing activity orders for the studied ruthenium complexes can be pointed out for these three species of *Candida*: C. *krusei*, C. *parapsilosis*, C. *tropicalis*: C7 > C2 ≥ C6 ≥ C1 ≥ C9 > C5 > C8 > C4 > C3; C7 ≥ C2 ≥ C6 ≥ C1 > C5 ≥ C8 > C9 > C3 > C4; C7 ≥ C2 ≥ C6 > C1 > C3 > C9 > C5 > C8 > C4, respectively. In the case of C. *glabrata* the activity order for the complexes is completely different: C1 ≥ C2 > C9 > C5 ≈ C7 ≈ C8 ≈ C6 ≈ C4 ≈ C3.
Table 1. *In vitro* antifungal activity of pentakis-dithiocarbamate diruthenium complexes and the corresponding free ligands (MIC, μg mL⁻¹/10⁻⁵mol L⁻¹) against different species of *Candida* by microdilution method.

| Compounds | Candida albicans | C. krusei | C. parapsilosis | C. tropicalis | C. glabrata |
|-----------|------------------|-----------|-----------------|--------------|------------|
|           | ATCC 119CL 01CL  |           |                 |              |            |
| L1        | 16 (11)          | 16 (11)   | 16 (11)         | 16 (11.2)    | 128 (89.4) |
| C1        | 8.0 (1.0)        | 16 (2.0)  | 16 (2.0)        | 16 (2.0)     | 16 (2.0)   |
| L2        | 16 (9.3)         | 16 (9.3)  | 16 (9.3)        | 64 (37)      | 64 (37)    |
| C2        | 8.0 (0.85)       | 16 (1.7)  | 16 (1.70)       | 8 (0.9)      | 8 (0.9)    |
| L3        | 64 (37)          | 32 (19)   | 32 (18.7)       | 128 (74.7)   | 32 (18.7)  |
| C3        | 64 (6.8)         | 128 (13.6)| 128 (13.6)      | 64 (6.8)     | 64 (6.8)   |
| L4        | 32 (21)          | 16 (10)   | 16 (10)         | 32 (21)      | 64 (42)    |
| C4        | 64 (7.3)         | 64 (7.3)  | 64 (7.3)        | 64 (7.3)     | 64 (7.3)   |
| L5        | 128 (64)         | 32 (16)   | 32 (16)         | 64 (32)      | 64 (32)    |
| C5        | 32 (3.0)         | 64 (5.9)  | 64 (5.9)        | 32 (3.0)     | 64 (5.9)   |
| L6        | 2.0 (1.2)        | 16 (9.5)  | 16 (9.45)       | 8 (4.7)      | 16 (9.5)   |
| C6        | 4.0 (0.43)       | 16 (1.7)  | 16 (1.71)       | 16 (1.7)     | 8.0 (0.86) |
| L7        | 8.0 (4.4)        | 16 (8.8)  | 16 (8.8)        | 8.0 (4.4)    | 32 (18)    |
| C7        | 4.0 (0.40)       | 16 (1.6)  | 16 (1.6)        | 8.0 (0.8)    | 8.0 (0.8)  |
| L8        | 128 (69.1)       | 128 (69.1)| 128 (69.1)      | 128 (69.1)   | 128 (69.1) |
| C8        | 64 (6.3)         | 64 (6.3)  | 128 (12.6)      | 64 (6.4)     | 64 (6.4)   |
| L9        | 8.0 (3.0)        | 128 (47.9)| 64 (24)         | 8.0 (3.0)    | 32 (12)    |
| C9        | 64 (4.1)         | 64 (4.1)  | 64 (4.1)        | 32 (2.1)     | 64 (4.1)   |
| RuCl₃     | >512 (196)       | >512 (196)| >512 (196)      | >512 (196)   | >512 (196) |
| AMB       | 0.50 (0.05)      | 1.00 (0.11)| 0.50 (0.05)    | 0.25 (0.03)  | 1.00 (0.11) |
| FLU       | 1.00 (0.33)      | 1.00 (0.33)| 32.0 (10.4)    | 1.00 (0.33)  | 32.0 (10.4) |

Considering the antifungal activity tests against *C. dubliniensis* (Table 2), the CD29 and the CD22 clinical isolates were the less susceptible species, but even for CD22 and the complex C1, and for C27 and C2 the obtained MIC values were comparable, and even lower (8.0 and 6.8 × 10⁻⁵ mol L⁻¹, respectively) than the obtained ones with FLU (10.4 × 10⁻⁵ mol L⁻¹). All complexes and analogous free ligands were also tested against the *C. dubliniensis* CD28 clinical isolate (Table 3). All complexes and all free ligands were active (MIC: 1.7–16.1 × 10⁻⁵ mol L⁻¹), except L8, that showed very low activity (MIC 69.1 × 10⁻⁵ mol L⁻¹). The decreasing activity order of the studied complexes was also similar to the previous ones: C7 > C6 > C2 > C5 > C9 > C8 > C4 > C3. Although the interesting results obtained, none of them showed lower MIC values than FLU, and as in all cases before, except for *C. glabrata*, the preliminary structure-activity relationship analysis shows that the mono-N-alkyl derivatives C3 and C4 are the less active compounds and the bis-N,N-dialkyldithiocarbamate complexes are the most active ones.

In the susceptibility tests of seven clinical isolates of *Paracoccidioides brasiliensis* (Table 4), it can be noticed that the obtained results of the different clinical isolates were quite similar (0.42–12.6 × 10⁻⁵ mol L⁻¹), but the clinical isolate MG05 was the most susceptible species (0.42–1.70 × 10⁻⁵ mol L⁻¹) and that the complexes were also more active than the corresponding free ligands (3–180 fold).
Table 2. *In vitro* susceptibility of species of *Candida dubliniensis* clinical isolates for L1, C1, L2 and C2 complexes by microdilution methods—MIC: μg mL⁻¹ (10⁻⁵ mol L⁻¹).

| Compounds | Candida dubliniensis clinical isolates |
|-----------|---------------------------------------|
|           | CD22 | CD23 | CD25 | CD27 | CD29 |
| L1        | 8.0 (5.6) | 4 (2.8) | 8 (5.6) | 4 (2.8) | 8 (5.6) |
| C1        | 64 (8.0) | 8.0 (1.0) | 8 (1.0) | 8 (1.00) | 32 (4.00) |
| L2        | 8.0 (4.6) | 4.0 (2.4) | 8.0 (4.8) | 8.0 (4.8) | 8.0 (4.8) |
| C2        | 64 (6.8) | 64 (6.8) | 64 (6.8) | 32 (3.4) | 64 (6.8) |
| AMB       | 0.50 (0.05) | 1.0 (0.10) | 0.50 (0.05) | 0.50 (0.05) | 1 (0.10) |
| RuCl₃     | >512 (196) | >512 (196) | >512 (196) | >512 (196) | >512 (196) |
| FLU       | 32.0 (10.2) | 1.00 (0.32) | 1.00 (0.32) | 32.0 (10.2) | 1.00 (0.32) |

Table 3. *In vitro* susceptibility—MIC: μg mL⁻¹ (10⁻⁵ mol L⁻¹) of *Candida dubliniensis* clinical isolate CD28 for pentakis-dithiocarbamate diruthenium complexes and free ligands by microdilution methods.

| Compounds | L1 | C1 | L2 | C2 | L3 | C3 | L4 | C4 | L5 | C5 |
|-----------|----|----|----|----|----|----|----|----|----|----|
|           | 8  | 16 | 8  | 16 | 16 | 64 | 16 | 64 | 32 | 32 |
| CD28      | (5.6) | (2.0) | (4.7) | (1.7) | (9.3) | (7.8) | (10) | (7.3) | (16.1) | (3.0) |
| L6 | C6 | L7 | C7 | L8 | C8 | L9 | C9 | AMB | FLU |
| CD28      | 16 | 16 | 16 | 16 | 128 | 64 | 64 | 64 | 0.50 | 1.00 |
|           | (9.5) | (1.7) | (8.7) | (1.6) | (69.1) | (6.3) | (24) | (4.1) | (0.11) | (0.33) |

Table 4. *In vitro* susceptibility of clinical isolates of *Paracoccidioides brasiliensis* for pentakis-dithiocarbamate diruthenium complexes by microdilution methods—MIC: μg mL⁻¹ (10⁻⁵ mol L⁻¹).

| Compounds | Paracoccidioides brasiliensis Clinical Isolates |
|-----------|-----------------------------------------------|
|           | MG05 | PB01 | PB18 | PB017 | 608 | B339 | MG04 |
| C1        | 16 (2.0) | 32 (4.0) | 16 (2.0) | 32 (4.0) | 32 (4.0) | 16 (2.0) | 16 (2.0) |
| C2        | 4.0 (0.42) | 8.0 (0.85) | 16 (1.7) | 8 (0.85) | 16 (1.7) | 4.0 (0.42) | 8.0 (0.85) |
| C3        | 64 (6.8) | 64 (6.8) | 64 (6.8) | 64 (6.8) | 64 (6.8) | 64 (6.8) | 64 (6.8) |
| C4        | 64 (7.3) | 64 (7.3) | 64 (7.3) | 64 (7.3) | 64 (7.3) | 64 (7.3) | 64 (7.3) |
| C5        | 64 (5.9) | 64 (5.9) | 64 (5.9) | 64 (5.9) | - | - | - |
| C6        | 16 (1.7) | 16 (1.7) | 16 (1.7) | 16 (1.7) | - | - | - |
| C7        | 16 (1.6) | 16 (1.6) | 16 (1.6) | 16 (1.6) | - | - | - |
| C8        | 128 (12.6) | 64 (6.3) | 128 (12.6) | 128 (12.6) | 128 (12.6) | 128 (12.6) | 128 (12.6) |
| C9        | 128 (8.18) | 64 (4.1) | 128 (8.2) | 128 (8.2) | 128 (8.2) | 128 (8.2) | 128 (8.2) |
| RuCl₃     | >512 (196) | >512 (196) | >512 (196) | >512 (196) | >512 (196) | >512 (196) | >512 (196) |
| AMB       | 0.50 (0.05) | 1.00 (0.11) | 0.50 (0.05) | 0.50 (0.05) | 0.50 (0.05) | 1.00 (0.11) | 0.50 (0.05) |
| FLU       | 1.00 (0.33) | 1.00 (0.33) | 32.0 (10.4) | 1.00 (0.33) | 1.00 (0.33) | 32.0 (10.4) | 1.00 (0.33) |

*There was not fungal growth viability.*

The complexes C2, C7, C6 and C1 showed the highest activities (respective MIC values: 0.42, 1.6, 1.7 and 2.0 × 10⁻⁵ mol L⁻¹) followed by compounds C5, C3, C4, C9 and C8 (5.9, 6.8, 7.3, 8.18 and 12.6 × 10⁻⁵ mol L⁻¹). The four former complexes really showed antifungal activity similar to FLU.
(0.33–10.4 × 10⁻⁵ mol L⁻¹). These results suggest that the similar derivatives with ethyl (C₂), tetramethylene and pentamethylene (C₆ and C₇), and methyl (C₁) moieties are the most active compounds.

The susceptibility tests of Cryptococcus neoformans (Table 5) were also performed and as observed before, the free ligands were less active than the ruthenium complexes (3–11 fold), but when the studied complexes are compared to each other, the results were different than the other ones described above. The N,N-dibenzylthiocarbamate diruthenium complex C₉ was the most active agent (MIC: 1.02 × 10⁻⁵ mol L⁻¹) followed by C₅, C₇, C₂, C₆ and C₁ with very similar MIC values (1.48–1.99 × 10⁻⁵ mol L⁻¹) and by C₈, C₄ and C₃ (3.16, 3.66 and 6.8 × 10⁻⁵ mol L⁻¹). In fact, in this case a preliminary structure-activity relationship shows a clear correlation between the steric hindrance of the N,N-dialkylsubstituents of the complexes and the antifungal activity: C₉ (N,N-dibenzy1) > C₅ (N,N-diisopropyl) ≥ C₇ (piperidinyl) ≥ C₂ (diethyl) ≥ C₆ (pyrrolidinyl) > C₁ (dimethyl). The mono-N-alkyl complexes – C₃ (mono-tert-butyl) and C₄ (mono-isopropyl) – and the morpholine derivative C₈, with an oxygen atom in the ring of the substituent, were the less active compounds. It is remarkable that C₉ showed itself almost as potent as FLU (0.65 × 10⁻⁵ mol L⁻¹).

| Compounds | Cryptococcus neoformans | Compounds | Cryptococcus neoformans |
|-----------|-------------------------|-----------|-------------------------|
| L₁        | 16.0 (11.2)             | L₆        | 16.0 (9.45)             |
| C₁        | 16.0 (1.99)             | C₆        | 16.0 (1.71)             |
| L₂        | 16.0 (9.34)             | L₇        | 16.0 (8.73)             |
| C₂        | 16.0 (1.70)             | C₇        | 16.0 (1.59)             |
| L₃        | 16.0 (9.34)             | L₈        | 64.0 (34.5)             |
| C₃        | 64.0 (6.80)             | C₈        | 32.0 (3.16)             |
| L₄        | 16.0 (10.2)             | L₉        | 128 (47.9)              |
| C₄        | 32.0 (3.66)             | C₉        | 16.0 (1.02)             |
| L₅        | 32.0 (16.0)             | RuCl₃     | >512 (196)              |
| C₅        | 16.0 (1.48)             | FLU       | 2.0 (0.65)              |

Only the acyclic derivatives C₁–C₅ could be tested on Sporotrich schenckii (Table 6) since the tests with the other complexes could not be performed due to cell growth problems. The N,N-dialkylthiocarbamate ruthenium complexes C₂–C₁ showed higher activity (MIC: C₂-0.85 and C₁-1.0 × 10⁻⁵ mol L⁻¹) followed by the mono-N-alkyl analogues C₄ and C₃ (MIC: C₄-14.8 and C₃-27.1 × 10⁻⁵ mol L⁻¹); the N,N-diisopropyl complex C₅ did not show interesting antifungal activity (MIC > 14.8 × 10⁻⁵ mol L⁻¹). C₁ and C₂ indeed showed MIC values that are closely comparable with those obtained with FLU (0.65 × 10⁻⁵ mol L⁻¹).

2.3. Cytotoxicity Assay

Results obtained from cytotoxicity assay are summarized in Table 7. The global analysis of the data showed a lower cytotoxicity for complexes C₃, C₄, C₅, C₆, C₇, C₈ and C₉, but the complexes C₁ and C₂ showed a higher toxicity. However, interestingly, even for the most toxic complexes C₁ and
their best *in vitro* antifungal activity was detected at concentrations 90- and 30-fold lower respectively, much smaller values than the IC₅₀ obtained on normal mammalian cells.

**Table 6.** In vitro susceptibility of clinical isolates of *Sporotrich schenckii* for pentakis-dithiocarbamate diruthenium (C₁–C₅) complexes by microdilution methods—MIC: μg mL⁻¹ (10⁻⁵ mol L⁻¹).

| Compounds | Cryptococcus neoformans |
|-----------|-------------------------|
| L₁        | 2.0 (1.4)               |
| C₁        | 8.0 (1.0)               |
| L₂        | 8.0 (4.7)               |
| C₂        | 8.0 (0.85)              |
| C₃        | 256 (27.1)              |
| C₄        | 125 (14.8)              |
| C₅        | >256 (14.8)             |
| RuCl₃     | >512 (196)              |
| FLU       | 2.0 (0.65)              |

**Table 7.** In vitro cytotoxicity of the studied pentakis-dithiocarbamate diruthenium complexes under normal cell line BHK (IC₅₀ values in μM).

|       | C₁  | C₂  | C₃  | C₄  | C₅  | C₆  | C₇  | C₈  | C₉  |
|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| BHK-21| 89  | 33  | >100| >100| >100| >100| >100| >100| >100|

3. Experimental

3.1. General Information

RuCl₃·3H₂O, D₂O, amphotericin-B (AMB) and fluconazole (FLU) (used as positive control), were purchased from Sigma-Aldrich (St Louis, MO, USA), dimethyl sulfoxide (DMSO; Merck Sharp & Dohme Ltd, Darmstadt, Germany). Other high purity reagents and solvents were used without purification. Dithiocarbamic acid sodium salts (NaS₂CNR₁R₂) were obtained through the classical and usual synthetic route (reaction between carbon disulfide and the corresponding amines) [42,50] and they were used as ligands (L₁–L₉) for the synthesis of the corresponding ruthenium complexes C₁–C₉ that were prepared following a procedure previously reported in the literature [50]. All compounds were fully characterized by the usual spectrometric and physicochemical techniques (IR, ESI-MS, ¹H and ¹³C-NMR spectra and elemental analysis). ¹H and ¹³C-NMR spectra were recorded using a Bruker Avance DPX200 MHz spectrometer (Bruker, Karlsruhe, Germany). Chemical shifts (δ in ppm) are referenced to internal solvent resonances and reported relative to SiMe₄. Infrared spectra were recorded on a Perkin Elmer 283B spectrophotometer (Perkin Elmer, MA, USA), measured in KBr (4,000–400 cm⁻¹) and in polyethylene (400–150 cm⁻¹) discs. Melting points were determined in the Fisher-Johns equipment and were not corrected. The ESI-MS analyses were conducted on a LCQFleet (Thermo Scientific, San Jose, CA, USA) mass spectrometer bearing an electrospray ionization (ESI) source and operating in the positive ion mode using conditions described elsewhere [65]. EPR spectra were registered in a Bruker EMX instrument (Bruker, Karlsruhe, Germany) [66] operating at
X-band (frequency 9.50 GHz, 20.12 mW, and 100 kHz frequency amplitude), using solid samples or frozen solutions, at 77 K, in Wilmad quartz tubes. The magnetic field was calibrated with 2,2-bis(4-tert-octylphenyl)-1-picrylhydrazyl (DPPH) as the external standard (g = 2.0036).

3.2. Chemistry: General Procedure for Preparation and Chemical Characterization of Complexes C1–C9 [50]

A reaction mixture consisting of an aqueous solution of RuCl3·3H2O and the corresponding sodium dithiocarbamate ligand L1–L9 (1:3 stoichiometric molar ratio), was stirred at room temperature for 24 h. The brown solid was collected by filtration, washed with water and dried. The dinuclear ruthenium dithiocarbamate complexes, C1–C9, obtained as pure compounds (TLC, HPLC and ESI(+)-MS), have been fully characterized (measurement of magnetic susceptibility (μeff), electron paramagnetic resonance (EPR) spectra, conductivity, cyclic voltammetry) [50,59–62].

α-Pentakis(N,N-dimethyldithiocarbamate)diruthenium [Ru2(S2CN(CH3)2)5] (C1): Yield 72%. m.p.: >300 °C; IR (cm⁻¹): 1537 m (N-CSS), 1012 (C-S), 277 (Ru-S), 209 (Ru-Ru); ¹H-NMR (200 MHz, DMSO-d6, δ in ppm): 3.58 (s); ¹³C-NMR (50 MHz, DMSO-d6, δ in ppm): 41.83 (s, CH₃), 191.75 (s, CS₂); ESI(+)-MS: m/z 803.52 [M⁺] = C₁₅H₃₀N₅Ru₂S₁₀Ru₂ = [Ru₂(S₂CN(CH₃)₂)₅]⁺.

α-Pentakis(N,N-diethyldithiocarbamate)diruthenium [Ru₂(S₂CN(CH₂CH₃)₂)₅] (C2): Yield 65%; m.p.: >300 °C; IR (cm⁻¹): 1508 m (N-CSS), 1009 (C-S), 278 (Ru-S), 209 (Ru-Ru); ¹H-NMR (200 MHz, DMSO-d₆, δ in ppm): 1.25 (6H), 4.22 (4H); ¹³C-NMR (50 MHz, DMSO-d₆, δ in ppm): 12.90 (s, CH₃), 44.33 (s, CH₂), 195.52 (s, CS₂); ESI(+)-MS: m/z 943.84 [M⁺] = C₂₅H₅₀N₅Ru₂S₁₀ = [Ru₂(S₂CN(CH₂CH₃)₂)₅]⁺.

α-Pentakis(N-tert-butyldithiocarbamate)diruthenium [Ru₂{S₂CN(C(CH₃)₃(H))₅}] (C3): Yield 71%; m.p.: 240 °C (decomp.); IR (cm⁻¹): 1530 (N-CSS), 1020 (C-S), 280 (Ru-S), 204 (Ru-Ru); ¹H-NMR (200 MHz, DMSO-d₆, δ in ppm): 1.49 (s); ¹³C-NMR (50 MHz, DMSO-d₆, δ in ppm): 30.18 (s, CH₃), 56.81 (s, CHMe₂), 202.51 (s, CS₂); ESI(+)-MS: m/z 943.85 [M⁺] = C₂₅H₅₀N₅Ru₂S₁₀Ru₂ = [Ru₂{S₂CN(C(CH₃)₃(H))₅}]⁺.

α-Pentakis(N-isopropylidithiocarbamate)diruthenium [Ru₂{S₂CN(CH(CH₃)₂)(H)}₅] (C4): Yield 73%; m.p.: >300 °C; IR (cm⁻¹): 1513 (C-N), 1030 (C-S), 279 (Ru-S), 203 (Ru-Ru); ¹H-NMR (200 MHz, DMSO-d₆, δ in ppm): 5.95 (18H), 7.26 (s, 3H); ¹³C-NMR (50 MHz, DMSO-d₆, δ in ppm): 18.63 (s, CH₃), 56.20 (s, CH), 195.01 (s, CS₂); ESI(+)-MS: m/z 873.83 [M⁺] = C₂₀H₄₀N₅Ru₂S₁₀ = [Ru₂{S₂CN(CH(CH₃)₂)(H)}₅]⁺.

α-Pentakis(N,N-diisopropylidithiocarbamate)diruthenium [Ru₂{S₂CN(CH(CH₃)₂)₅}] (C5): Yield 62%; m.p.: >300 °C; IR (cm⁻¹): 1483 (N-CSS), 1032 (C-S), 279 (Ru-S), 203 (Ru-Ru); ¹H-NMR (200 MHz, DMSO-d₆, δ in ppm): 4.84 (36H), 6.85 (m, 6H); ¹³C-NMR (50 MHz, DMSO-d₆, δ in ppm): 13.88 (s, CH₃), 56.22 (s, CH), 194.09 (s, CS₂); ESI(+)-MS: m/z 1083.86 [M⁺] = C₃₅H₇₀N₅Ru₂S₁₀ = [Ru₂{S₂CN(CH(CH₃)₂)₅}]⁺.
α-Pentakis(N,N-dipyrrolidinyldithiocarbamate)diruthenium \([\text{Ru}_2(\text{S}_2\text{C}(\text{N}(-\text{CH}_2-)\text{4})_5)\text{]}\) (C6): Yield 78%; m.p.: 210 °C (decomp.); IR (cm\(^{-1}\)): 1492 (N-CSS), 1028 (C-S), 279 (Ru-S), 204 (Ru-Ru); \(^1\)H-NMR (200 MHz, DMSO-\(d_6\), δ in ppm): 3.3–4.0(NCH\(_2\)), 2.2–1.9(CH\(_2\)); ESI(+)-MS: \(m/z\) 933.86 [M\(^+\) = C\(_{25}\)H\(_{40}\)N\(_5\)Ru\(_2\)S\(_{10}\) = [Ru\(_2\)(S\(_2\)CN(-CH\(_2\)-CH\(_2\)-)]\(^+\)].

α-Pentakis(N,N-dipiperidinyldithiocarbamate)diruthenium \([\text{Ru}_2(\text{S}_2\text{C}(\text{N}(-\text{CH}_2-)\text{5})_5)\text{]}\) (C7): Yield 71%; m.p.: >300 °C; IR (cm\(^{-1}\)): 1495 (N-CSS), 1003 (C-S), 282 (Ru-S), 202 (Ru-Ru); ESI(+)-MS: \(m/z\) 1003.66 [M\(^+\) = C\(_{30}\)H\(_{50}\)N\(_5\)Ru\(_2\)S\(_{10}\) = [Ru\(_2\)(S\(_2\)CN(-CH\(_2\)-)]\(^+\)].

α-Pentakis(N,N-morpholinyldithiocarbamate)diruthenium \([\text{Ru}_2\{\text{S}_2\text{C}(\text{N}(-\text{CH}_2\text{O}-(\text{CH}_2-)\text{2}))_5\}\text{]}\) (C8): Yield 79%; m.p.: 210 °C (decomp.); IR (cm\(^{-1}\)): 1484 (N-CSS), 1022 (C-S), 277 (Ru-S), 204 (Ru-Ru); ESI(+)-MS: \(m/z\) 1005.83 [M\(^+\) = C\(_{25}\)H\(_{40}\)N\(_5\)Ru\(_2\)S\(_{10}\) = [Ru\(_2\)(S\(_2\)C(N(-(CH\(_2\)-2O-(CH\(_2\)-2))]\(^+\)].

α-Pentakis(N,N-dibenzyldithiocarbamate)diruthenium \([\text{Ru}_2\{\text{S}_2\text{C}(\text{N}(\text{CH}_2\text{C}_6\text{H}_5))_2\}5\}\text{]}\) (C9): Yield 71%; m.p.: 275 °C (decomp.); IR (cm\(^{-1}\)): 1494 (N-CSS), 1010 (C-S), 282 (Ru-S), 202 (Ru-Ru); ESI(+)-MS: \(m/z\) 1564.16 [M\(^+\) = C\(_{75}\)H\(_{70}\)N\(_5\)Ru\(_2\)S\(_{10}\) = [Ru\(_2\)(S\(_2\)C(N(CH\(_2\)C\(_6\)H\(_5\)))\(_2\)]\(^+\)].

3.3. Antifungal Activity

3.3.1. Microorganism Origin

Microorganisms were obtained from the American Type Culture Collection and included *C. albicans* (ATCC 18804) and two clinical isolates: 01CL and 119CL), *C. glabrata* (ATCC 2001), *C. krusei* (ATCC 200298), *C. parapsilosis* (ATCC 20019), *C. tropicalis* (ATCC 750), *C. dubliniensis* (six clinical isolates: CD22, CD23, CD25, CD27, CD28 and CD29), *Paracoccidioides brasiliensis* (seven clinical isolates: MG05, PB01, PB18, B339, 608, PB1017, MG04), *Cryptococcus neoformans* (ATCC 32608) and *Sporothrix schenckii* (ATCC 10212). The isolates of *Candida* spp. were maintained on Sabouraud dextrose agar (SDA, Difco Laboratories, Detroit, MI, USA) and potato dextrose agar (PDA, Difco Laboratories) to stimulate the conidia production. *S. schenckii* was maintained on BHI medium with glucose 5% (agar and syrup) or RPMI 1640 (Sigma) supplemented with 5% dextrose and *P. brasiliensis* on Fava-netto medium and incubated at 37 °C to obtain the yeast phase and was weekly replicated to maintain the sample viable.

3.3.2. Susceptibility Testing

Susceptibility tests were performed according to guidelines of CLSI Broth microdilution reference method M27A3 for the yeasts and M38A2 for moulds (CLSI, 20008) on RPMI 1640 with L-glutamine and without bicarbonate (Difco Laboratories) buffered at pH7.0 with 0.165 mol/L [3-(N-morpholino)propanesulfonic acid] (Sigma) [67]. The ruthenium complexes C1–C9 and the corresponding free ligands (L1–L9) were dissolved in DMSO and synthetic RPMI medium. The antifungal tests with the corresponding ligands L1–L9 and even with ruthenium trichloride were also made for comparison. All studied compounds were dissolved in RPMI medium. Serial dilutions were performed using RPMI diluent. One hundred microlitres of each concentration (range 1.0–512 g mL\(^{-1}\), or in some cases when specified 0.5–256 g mL\(^{-1}\)) was distributed in microplates. Stock inoculum
suspensions were prepared in sterile saline (0.85%) containing 1% Tween 20 from 7-day-old cultures
grown on PDA slants. After heavy particles were allowed to settle, the turbidity of the supernatants was
measured spectrophotometrically (Micronal B542, São Paulo, SP, Brazil) at 530 nm, and the transmission
was adjusted between 80% and 82%, yielding an initial inoculum of $1–5 \times 10^6$ CFU mL$^{-1}$. Each
suspension was diluted 1:50 in medium to obtain twice the desired inoculum ($0.5–1 \times 10^4$ CFU mL$^{-1}$).
Susceptibility was determined in sterile flat-bottom 96-well microplates. As a control for growth and
sterility, RPMI was used without drugs or solvents. Solvent was added to medium as a control for
toxicity. All tests were performed in duplicate. The endpoints were determined visually by comparison
with that drug free growth control experiment. Minimum inhibitory concentrations (MICs) were
defined as the lowest drug concentrations that provided for which optically clear, except for
Fluconazole (FLU) (endpoint allowing 50% reduction in growth) and they were expressed in μg L$^{-1}$.
Amphotericin B (AMB) and Fluconazole (FLU) were included as positive antifungal controls. Stock
solution was prepared by dissolving the drugs in RPMI at a concentration of 1.5 mg L$^{-1}$. For antifungal
testing, concentrations range 0.03–16 μg L$^{-1}$ to AMB and 0.25–128 μg L$^{-1}$ to FLU were used. The
results were read after 48 h incubation at 35 ℃.

3.3.3. Cytotoxicity Assay

Cell Cultures:

BHK-21 cells (Baby Hamster Kidney epithelium) were grown in T-25 flasks in 5.0 mL of RPMI
medium (Sigma-Aldrich) containing 10% fetal calf serum (Cultilab, São Paulo, SP, Brazil) and
supplemented with antibiotics ampicillin (100 U mL$^{-1}$) and streptomycin (100 mg mL$^{-1}$). The cells
were maintained in the logarithmic phase in 5% CO$_2$ atmosphere at 37 ℃ and subcultured by
harvesting with 0.05% trypsin-ethylenediaminetetraacetic acid (EDTA) solution.

Cytotoxicity Assay Experiments:

The cytotoxic activity of the compounds towards normal cell line was evaluated through the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay[68]. Briefly, $1.0 \times 10^3$ cells in
100 μL of culture medium were seeded in 96-well microplates and cultivated as described above. After
48 h, the medium was removed and replaced with a fresh one containing different concentrations ($10^{-7}$
to $10^{-4}$mol L$^{-1}$) of studied compounds prepared in sixplicate. After 120 h, each well was treated with
10 μL of 5 μg mL$^{-1}$ MTT aqueous solution and after 4 h of incubation, the medium was aspirated and
100 μL of DMSO was added. The cytotoxic effect induced by compounds was detected by measuring
the absorbance at 570 nm using a Stat Fax-2100 (Awareness Technology Inc., Palm City, FL, USA)
microplate reader. Mean absorbance for each compound concentration was expressed as a percentage
relative to the control group (untreated cells), and plotted vs. concentration. IC$_{50}$ values represent the
drug concentrations that reduced the mean absorbance at 570 nm to 50% of those in the untreated
control wells (or determination of inhibitory concentration to 50% cell viability).

4. Conclusions

In this work, we synthesized and characterized a set of nine dithiocarbamate ligands and the nine
 corresponding dirutheniumpentakis-dithiocarbamate complexes in good yields. All synthesized
Molecules 2014, 19 5415

complexes (C1–C9) (C1: N,N-dimethyl-; C2: N,N-diethyl-; C3: N-mono-terc-butyl-; C4: N-mono-(iso-propyl)-; C5: N-di-(iso-propyl)-; C6: N-pyrrolidinyl-; C7: N-piperidinyl; C8: N-morpholinyl-and C9: N,N-dibenzyl-dithiocarbamates) were submitted to in vitro tests against some fungi with clinical interest. Except for Candida glabrata, the less susceptible fungal species, all other species related to IFIs showed high susceptibility to almost all studied complexes and with good antifungal activity results (MIC values in the order of 10⁻⁵ mol L⁻¹ to 10⁻⁸ mol mL⁻¹). In some cases, the obtained MIC values were close or even lower than the obtained MIC value for the classic clinically used antifungal agent, Fluconazole (FLU). For instance, considering candidiasis and paracoccidioidomycosis that are usually related to IFIs in Latin America, the diethyl- (C2), the pyrrolidinyl- (C6) and the piperidinyl-(C7) diruthenium complexes show remarkably antifungal activities, while for cryptococcosis cases the N,N-dibenzyl complex (C9) might be indicated and for sporotrichosis, the simpler N,N-dimethyl- (C1) or N,N-diethyl-(C2) analogous complexes can be used. The results showed that the complexes are more active than the corresponding free ligands and these data can be explained considering the higher lipophilicity of the complexes [53]. Preliminary structure-activity relations (SAR) suggest a strong influence from steric and lipophilic parameters in the antifungal activity of the studied ruthenium complexes and these data are corroborated by a quite recent QSAR study [69] in which it was reported the dependence of the antifungal activity from several known antifungal agents on the lipophilic and steric effects. Cytotoxic assays (IC₅₀) showed that the complexes are not so toxic (IC₅₀ values are much higher than MIC values). Finally, it can be concluded that ruthenium dinuclear pentakis-dithiocarbamate complexes can be considered as potential novel antifungal agents with high potency and low citotoxicity for the development of new drugs to attack the terrible worldwide health problem of invasive fungal infections (IFIs) and emerging infectious diseases (EIDs).

Acknowledgments

The authors thank the Foundation for Research of the State of Minas Gerais (FAPEMIG): PPM VII CEX 208/13 and “Rede Mineira de Química” (RQ-MG REDE 113/10), and “National Council of Technological and Scientific Development” (CNPq).

Author Contributions

L.J.N. synthesized all ligands and complexes and participated in all steps of the research; M.H.A. helped a lot in the complexes characterization and participated on the writing of manuscript; S.R.O. registered the ESI-MS spectra and participated on the writing of manuscript; M.T.P.L. and A.C.A.S. effected the cytotoxicity assays and participated on the writing of manuscript. T.F.F.M., C.V.B.M. and M.A.R.S. effected the antifungal assays and participated on the writing of manuscript; A.M.D.C.F. registered the EPR spectra and participated on the writing of manuscript.

Conflicts of Interest

The authors declare no conflict of interest.
References

1. Jones, K.E.; Patel, N.G.; Levy, M.A.; Storeygard, A.; Balk, D.; Gittleman, J.L.; Daszak, P. Global trends in emerging infectious diseases. *Nature* **2008**, *451*, 990–993.

2. Brown, G.; Denning, D.; Gow, N.; Levitz, S.; Netea, M.; White, T. Hidden killers: Human fungal infections. *Sci. Translat. Med.* **2012**, *4*, 1–9.

3. Brown, G.; Denning, D.; Levitz, S. Tackling human fungal infections. *Science* **2012**, *336*, 647–647.

4. Ascioglu, S.; Rex, J.; de Pauw, B.; Bennett, J.; Bille, J.; Crokaert, F.; Denning, D.; Donnelly, J.; Edwards, J.; Erjavec, Z.; *et al*. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus. *Clin. Infect. Dis.* **2002**, *34*, 7–14.

5. Luna, E.J.A. The emergence of emerging diseases and emerging and reemerging infectious diseases in Brazil. *Rev. Bras. Epidemiol.* **2002**, *5*, 229–243.

6. Pfaffer, M.; Boyken, L.; Hollis, R.; Messer, S.; Tendolkar, S.; Diekema, D. *In vitro* susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: Global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. *J. Clin. Microbiol.* **2005**, *43*, 3807–3810.

7. Pfaffer, M.; Diekema, D. Rare and emerging opportunistic fungal pathogens: Concern for resistance beyond Candida albicans and Aspergillus fumigatus. *J. Clin. Microbiol.* **2004**, *42*, 4419–4431.

8. Travassos, L.R.; Taborda, C.P. Paracoccidioidomycosis: Advances in treatment incorporating modulators of the immune response. *J. Invas. Fungal Infect.* **2011**, *5*, 1–6.

9. Sundriyal, S.; Sharma, R.; Jain, R. Current advances in antifungal targets and drug development. *Curr. Med. Chem.* **2006**, *13*, 1321–1335.

10. Cowen, L.E. The evolution of fungal drug resistance: Modulating the trajectory from genotype to phenotype. *Nat. Rev. Microbiol.* **2008**, *6*, 187–198.

11. VandenBossche, H.D.; Warnock, W.; Dupont, B.; Kerridge, D.; Sengupta, S.; Improvisi, L.; Marichal, P.; Odds, F.C.; Provost, F.; Ronin, O. Mechanisms and clinical impact of antifungal drug-resistance. *J. Med. Vet. Mycol.* **1994**, *32*, 189–202.

12. Odds, F.C.; Brown, A.J.P.; Gow, N.A.R. Antifungal agents: Mechanisms of action. *Trends Microbiol.* **2003**, *11*, 272–279.

13. Brammer, K.W.; Farrow, P.R.; Faulkner, J.K. Pharmacokinetics and tissue penetration of fluconazole in humans. *Rev. Infect. Dis.* **1990**, *12* (Suppl 3), S318–S326.

14. Vandeputte, P.; Ferrari, S.; Coste, A.T. Antifungal resistance and new strategies to control fungal infections. *Int. J. Microbiol.* **2012**, *2012*, 713687:1–713687:26.

15. Espinellingoff, A.; Shadomy, S.; Gebhart, R.J. *In vitro* studies with R 51,211 (itraconazole). *Antimicrob. Agents Chemother.* **1984**, *26*, 5–9.

16. Denning, D.; Venkateswarlu, W.K.; Oakley, K.L.; Anderson, M.J.; Manning, N.J.; Stevens, D.A.; Warnock, D.W.; Kelly, S.L. Itraconazole resistance in *Aspergillus fumigates*. *Antimicrob. Agents Chemother.* **1997**, *41*, 1364–1368.

17. Chiou, C.; Groll, A.; Walsh. T. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer. *Oncologist* **2000**, *5*, 120–135.
18. Sabo, J.A.; Abdel-Rahman, S.M. Voriconazole: A new triazole antifungal. *Ann. Pharmacother.* **2000**, *34*, 1032–1043.
19. De Sarro, A.; la Camera, E.; Fera, M.T. New and investigational triazole agents for the treatment of invasive fungal infections. *J. Chemother.* **2008**, *20*, 661–671.
20. Yamazumi, T.; Pfäffer, M.A.; Messer, S.A.; Houston, A.; Hollis, R.J.; Jones, R.N. *In vitro* activities of ravuconazole (BMS-207147) against 541 clinical isolates of *Cryptococcus neoformans*. *Antimicrob. Agents Chemother.* **2000**, *44*, 2883–2886.
21. Pfäffer, M.A.; Diekema, D.J.; Messer, S.A.; Boyken, L.; Hollis, R.J.; Jones, R.N. *In vitro* susceptibilities of rare Candida bloodstream isolates to ravuconazole and three comparative antifungal agents. *Diagn. Microbiol. Infect. Dis.* **2004**, *48*, 101–105.
22. Pfäffer, M.A.; Messer, S.A.; Boyken, L.; Rice, C.; Tendolkar, S.; Hollis, R.J.; Diekema, D.J. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. *J. Clin. Microbiol.* **2004**, *42*, 3137–3141.
23. Fera, M.T.; la Camera, E.; de Sarro, A. New triazoles and echinocandins: Mode of action, *in vitro* activity and mechanisms of resistance. *Expert Rev. Anti-Infective Ther.* **2009**, *7*, 981–998.
24. Bossche, H.V. Echinocandins—An update. *Expert Opin. Ther.* **2002**, *12*, 151–167.
25. Shao, P.L.; Huang, L.M.; Hsueh, P.R. Invasive fungal infection-laboratory diagnosis and antifungal treatment. *J. Microbiol. Immunol. Infect.* **2006**, *39*, 178–188.
26. Perlin, D.S. Resistance to echinocandin-class antifungal drugs. *Drug Resist. Update* **2007**, *10*, 121–130.
27. Pfäffer, M.A. Antifungal drug resistance: Mechanisms, epidemiology, and consequences for treatment. *Am. J. Med.* **2012**, *125*, S3–S13.
28. Larson, R.H.; Walker, J.C. Thiram for smut control in onion set plantings. *Phytopathology* **1953**, *43*, 596–597.
29. Sharma, P.D. *Plant Pathology*, 1st ed.; Rastogi Publications: New Delhi, India, 2004; pp. 14, 15.
30. Engst, R.; Schnaak, W. Residues of dithiocarbamate fungicides and their metabolites on plant foods. *Residue Rev.* **1974**, *52*, 45–67.
31. IUPAC. Applied Chemistry Division Terminal pesticide residues: Ethylenethiourea. *Pure Appl. Chem.* **1977**, *49*, 675–689.
32. Liesivuori, J.; Savolaiken, K. Dithiocarbamates. *Toxicology* **1994**, *91*, 37–42.
33. EBDC Fact sheet. Available online: http://www.pan-uk.org/pestnews/Actives/ebdcs.htm (accessed on 12 April 2011).
34. Clifford, D.P.; Carson, C.M. The synthesis and biological-activity of some potentially fungicidal zinc ethylenebis(dithiocarbamate)-amine complexes. *Pestic. Sci.* **1988**, *23*, 92–102.
35. Phinney, J.T.; Bruland, K.W. Trace metal exchange in solution by the fungicides Ziram and Maneb (dithiocarbamates) and subsequent uptake of lipophilic organic zinc, copper and lead complexes into phytoplankton cells. *Environ. Toxicol. Chem.* **1977**, *16*, 2046–205.
36. Arora, A.; Sud, D.; Sharma, J.R.; Arora, C.L. Transition metal dialkyldithiocarbamates and their antifungal activity. *Asian J. Chem.* **2003**, *15*, 715–719.
37. Desai, R.M.; Shah, M.K.; Shah, V.H. Preparation and antimicrobial screening of Cu(II), Ni(II), Zn(II) and Cd(II) complexes. *E-J. Chem.* **2006**, *3*, 137–141.
38. Golcu, A.; Yavuz, P. Spectral, analytical, thermal, and antimicrobial studies of novel sodium 2-[4-(2-hydroxy-3-isopropylaminopropoxy)phenyl]acetamide(atenolol)dithiocarbamate and its divalent transition metal complexes. *Russ. J. Coord. Chem.* 2008, 34, 106–114.

39. Mohamed, G.G.; Ibrahim, N.A.; Attia, H.A.E. Synthesis and anti-fungicidal activity of some transition metal complexes with benzimidazole dithiocarbamate ligand. *Spectrochim. Acta A* 2009, 72, 610–615.

40. Ferreira, I.P.; de Lima, G.M.; Paniago, E.B.; Takahashi, J.A.; Krambrock, K.; Pinheiro, C.B.; Wardell, J.L.; Visentine, L.C. Synthesis, characterization, structural and biological aspects of copper(II) dithiocarbamate complexes—Part II, \([\text{Cu}\{S_2\text{CN(Me)}(R^1)\}]_{2}\), \([\text{Cu}\{S_2\text{CN(Me)}(R^2)\}]_{2}\) and \([\text{Cu}\{S_2\text{CN}(R^3)(R^4)\}]_{2}\), \(R^1 = \text{CH}_2\text{CH} (\text{OMe})_2\), \(R^2 = \text{2-methyl-1,3-dioxolane}\), \(R^3 = \text{CH}_2(\text{CH}_2)\text{NCHPhOCH}_2\text{Ph}\) and \(R^4 = \text{CH}_2\text{CH}_2\text{OH}\). *J. Mol. Struct.* 2013, 1048, 357–366.

41. Menezes, D.C.; Vieira, F.T.; de Lima, G.M.; Porto, A.O.; Cortes, M.E.; Ardisson, J.D.; Albrecht-Schmitt, T.E. Tin(IV) complexes of pyrrolidinedithiocarbamate: Synthesis, characterization and antifungal activity. *Eur. J. Med. Chem.* 2005, 40, 1277–1282.

42. Menezes, D.C.; Vieira, F.T.; de Lima, G.M.; Wardell, J.L.; Cortes, M.E.; Ferreira, M.P.; Soares, M.A.; Boas, A.V. The *In vitro* antifungal activity of some dithiocarbamate organotin(IV) compounds on Candida albicans—A model for biological interaction of organotincomplexes. *Appl. Organomet. Chem.* 2008, 22, 221–226.

43. Shanker, K; Rohini, R, Ravinder, V.; Reddy, P.M.; Ho, Y.P. Ru(II) complexes of N4 and N2O2 macrocyclic Schiff base ligands: Their antibacterial and antifungal studies. *Spectrochim. Acta A* 2009, 73, 205–211.

44. Thangadurai, T.D.; Ihm, S.K. Ruthenium(II) complexes derived from substituted cyclobutane and substituted thiazole Schiff base ligands. Synthetic, spectral, catalytic and antimicrobial studies. *Synth. React. Inorg. Met.-Org. Chem.* 2005, 35, 499–507.

45. Jayabalakrishnan, C.; Karvembu, R.; Natarajan, K. Catalytic and antimicrobial activities of new ruthenium(II) unsymmetrical Schiff base complexes. *Transit. Met. Chem.* 2002, 27, 790–794.

46. Karvembu, R.; Jayabalakrishnan, C.; Natarajan, K. Thiobis(betadiketonato)-bridged binuclear ruthenium(III) complexes containing triphenylphosphine or triphenylarsine. Synthetic, spectral, catalytic and antimicrobial studies. *Transit. Met. Chem.* 2002, 27, 574–579.

47. Zakeeruddin, S.M.; Fraser, D.M.; Nazeeruddin, M. K.; Gratzel, M. Towards mediator design: Characterization of tris-(4,4-substituted-2,2-bipyridine) complexes of iron(II), ruthenium (II) and osmium(II) as mediators for glucose oxidase of *Aspergillus niger* and other redox proteins. *J. Electroanal. Chem.* 1992, 332, 253–283.

48. Nogueira, L.J.; Resende, M.A.; Oliveira, S.R.; Araujo, M.H.; Magalhães, T.F.F., Oliveira, M.; Martins, C.V.B.; Lopes, M.T.P.; Silva, A.C.A.; Donnici, C.L. *In vitro* susceptibility of *Aspergillus* spp. to dithiocarbamateorganoruthenium compounds. *Mycoses* 2011, 54, 323–329.

49. Sridhar, H.; Jayshree, R.S.; Bapsy, P.P.; Appaji, L.; Kumar, M.N.; Shaifiulla, M.; Vijay Kumar, B.R. Invasive aspergillosis in cancer. *Mycoses* 2002, 45, 358–363.
52. Klock, C.; Cerski, M.; Dargel, A.; Goldani, L.Z. Case report. Disseminated aspergillosis complicating pregnancy. *Mycoses* 2002, 45, 408–410.

53. Thompson, K.H.; Orvig, C. Boon and bane of metal ions in medicine. *Science* 2003, 300, 936–939.

54. Biersack, B.; Diestel, R.; Jagusch, C.; Sasse, F.; Schobert, R. Metal complexes of natural melophlins and their cytotoxic and antibiotic activities. *J. Inorg. Biochem.* 2009, 103, 72–76.

55. Ramos, A.I.; Braga, T.M.; Braga, S.S. Ru(II)-Based Antimicrobials: Looking beyond organic drugs. *Mini-Rev. Med. Chem.* 2012, 12, 227–235.

56. Clarke, M.J. Ruthenium metallopharmaceuticals. *Coord. Chem. Rev.* 2003, 236, 209–233.

57. Nagy, E.M.; Ronconi, L.; Nardon, C.; Fregona, D. Noble metal-dithiocarbamates precious allies in the fight against cancer. *Mini-Rev. Med. Chem.* 2012, 12, 1216–1229.

58. Brabec, V.; Novakova, O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. *Drug Resist. Update* 2006, 9, 111–122.

59. Donnici, C.L.; Araujo, M.H. Detailed physical-chemical and spectrometric characterisation of neutral dinuclear dithiocarbamate ruthenium complexes with *In vitro* antifungal activity. *Mycoses* 2012, 55, 102–103.

60. Giovagnini, L.; Mancinetti, E.; Ronconi, L.; Sitran, S.; Marchio, L.; Castagliuolo, I.; Brun, P.; Trevisan, A.; Fregona, D. Preliminary chemico-biological studies on Ru(III) compounds with S-methyl pyrrolidine/dimethyl dithiocarbamate. *J. Inorg. Biochem.* 2009, 103, 774–778.

61. Hendrikson, A.R.; Hope, J.M.; Martin, R.L.; Tris- and pentakis-dialkyldithiocarbamates of ruthenium [Ru(S2CNR2)3]n and [Ru2(S2CNR2)5]n (n = 1, 0, and −1): Chemical and electrochemical interrelations. *J. Chem. Soc. Dalton Trans.* 1976, 1976, 2032–2039.

62. Wheeler, S.H.; Mattson, B.M.; Miessler, G.L.; Pinolet, L.H. Electrochemical and chemical properties of dithiocarbamate complexes of Ruthenium(II), Ruthenium(III), and Ruthenium(IV). *Inorg. Chem.* 1978, 17, 340–350.

63. Ivanova, B.; Spiteller, M. Solid-state UV-MALDI-MS assay of transition metal dithiocarbamate fungicides. *Environ. Sci. Pollut. Res.* 2014, 21, 1163–1177.

64. Kumbhakar, D.; Sarkar, B.; Das, A.; Das, A.K.; Mobin, S.M.; Fiedler, J.; Kaim, W.; Lahiri, G.K. Valence structures of the diastereomeric complexes meso- and rac-[Ru2(acaca)4(μ-Q)]n (n = 2−, 1−, 0, 1+, 2+) with the multiple quinonoid bridging ligand Q = 1,2,4,5-tetraimino-3,6-diketocyclohexane. *Dalton Trans.* 2009, doi:10.1039/B906900C.

65. Oliveira, S.R.; Nogueira, L.J.; Augusti, R.; Stoianoff, M.A.R.; Aguilar, C.M.; Rocha, W.R.; Donnici, C.L. Influence of oxidation state of sulfur on the dissociation of [Tz-(CH2)n-S(O)m-(CH2)n−Tz + Na+] adducts generated by electrospray ionization (Tz = tetrazole ring; n = 2, 3; m = 0, 1, 2). *Rapid Commun. Mass Spectrom.* 2012, 26, 377–384.

66. Silveira, V.C.; Abbott, M.P.; Cavicchioli, M.; Goncalves, M.B.; Pettrilli, H.M.; de Rezende, L.; Amaral, A.T.; Fonseca, D.E.P.; Caramori, G.F.; Ferreira, A.M.D. Peculiar reactivity of a di-imine copper(II) complex regarding its binding to albumin protein. *Dalton Trans.* 2013, 42, 6386–6396.

67. National Committee for Clinical Laboratory Standards. *Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi*, In Approved Standard M38-A2; NCCLS: Wayne, PA, USA, 2002.
68. Mosmann, T. Rapid Colorimetric assay for cellular growth and survival. *J. Immunol Meth.* **1983**, *65*, 55–63.

69. Katritzky, A.R.; Slavov, S.H.; Dobchev, D.A.; Karelson, M. QSAR modeling of the antifungal activity against *Candida albicans* for a diverse set of organic compounds. *Bioorg. Med. Chem.* **2008**, *16*, 7055–7069.

*Sample Availability*: Not available.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).